Regeneron Pharmaceuticals (NASDAQ:REGN) Receives “Outperform” Rating from Royal Bank of Canada

Royal Bank of Canada reaffirmed their outperform rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note published on Tuesday,Benzinga reports. Royal Bank of Canada currently has a $943.00 price target on the biopharmaceutical company’s stock.

REGN has been the topic of several other reports. Citigroup raised Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price target for the company from $600.00 to $700.00 in a report on Wednesday, May 14th. Truist Financial reduced their price objective on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a “buy” rating for the company in a research report on Wednesday, April 30th. Cantor Fitzgerald initiated coverage on Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They issued an “overweight” rating and a $695.00 target price on the stock. Wells Fargo & Company dropped their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $700.00 and set an “overweight” rating on the stock in a report on Wednesday, April 30th. Finally, UBS Group cut their price objective on shares of Regeneron Pharmaceuticals from $768.00 to $633.00 and set a “neutral” rating for the company in a research report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $890.60.

Regeneron Pharmaceuticals Price Performance

REGN opened at $603.26 on Tuesday. The company’s 50-day simple moving average is $589.51 and its two-hundred day simple moving average is $671.75. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The stock has a market capitalization of $65.13 billion, a P/E ratio of 15.76, a P/E/G ratio of 2.34 and a beta of 0.43. Regeneron Pharmaceuticals has a 52-week low of $520.50 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.03 billion for the quarter, compared to analysts’ expectations of $3.40 billion. During the same period in the previous year, the firm earned $9.55 earnings per share. The firm’s revenue for the quarter was down 3.7% on a year-over-year basis. As a group, analysts predict that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.58%. The ex-dividend date of this dividend is Tuesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.96%.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Pinney & Scofield Inc. bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth about $25,000. E Fund Management Hong Kong Co. Ltd. boosted its holdings in shares of Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 31 shares during the period. Activest Wealth Management grew its stake in Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 21 shares in the last quarter. Costello Asset Management INC bought a new position in Regeneron Pharmaceuticals in the first quarter worth approximately $27,000. Finally, Saudi Central Bank purchased a new position in Regeneron Pharmaceuticals during the 1st quarter worth $27,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.